25Serious

David Branch

David Branch

Ask VT AI

View News Summary

Novartis is in advanced talks to acquire U.S. biotech Avidity Biosciences for over $12 billion, bolstering its neuroscience and RNA strategy.
Controversial Israeli bills aim to halt Netanyahu's trial and block Bennett's election bid, sparking concerns over democracy and rule of law.
Russia tests nuclear-powered cruise missile, raising concerns over technical challenges and strategic implications.

20 hours

United States Politics

Discover the latest news, candidates,  and key topics of US politics

Ask VT AI

View News Summary

Novartis is in advanced talks to acquire U.S. biotech Avidity Biosciences for over $12 billion, bolstering its neuroscience and RNA strategy.
Controversial Israeli bills aim to halt Netanyahu's trial and block Bennett's election bid, sparking concerns over democracy and rule of law.
Russia tests nuclear-powered cruise missile, raising concerns over technical challenges and strategic implications.

20 hours

United States Politics

Discover the latest news, candidates,  and key topics of US politics

Most Reported By
News from David Branch